Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00425256 · ClinicalTrials.gov registry record · Phase 2
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
A Phase 2 study, sponsored by Palatin Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00425256 is a Phase 2 study that has completed, run by Palatin Technologies.
The verdict
NCT00425256, a Phase 2 study, has completed, sponsored by Palatin Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.
Interventions
- DRUG Bremelanotide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2006-02 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00425256
The ClinicalTrials.gov registry entry for NCT00425256 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Palatin Technologies, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bremelanotide is the first listed.
NCT00425256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00425256 about?
NCT00425256 is a clinical study titled "Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)". This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.
What is the current status of trial NCT00425256?
This trial is currently completed. It is a Phase 2 study. The study started on 2006-02. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00425256?
The interventions under investigation include: Bremelanotide (DRUG).
Who is sponsoring clinical trial NCT00425256?
This trial is sponsored by Palatin Technologies, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.